ICICI Securities has issued a buy rating on Pfizer with a target price of ₹6,000 in its research report dated July 10, 2026. According to the brokerage's analysis, the pharmaceutical company's strong brand portfolio and operational improvements position it favorably for future growth.
In its FY26 annual report, Pfizer has highlighted key brands including Prevenar-13, Eliquis and Zavicefta as primary revenue growth drivers. As reported by ICICI Securities, newly launched brands including Prevenar-20, Emblaveo and Nurtec have been well received by the market. The company has implemented a targeted marketing approach towards prescribers, institutions and patients, utilizing digital channels for patient and doctor education.
In FY26, Pfizer optimized its sourcing and overhead costs, resulting in gross margin improvement of 43 basis points and EBITDA margin improvement of 343 basis points. According to ICICI Securities, these operational improvements have enhanced the company's profitability and efficiency metrics.
The company's tie-up with Cipla for four key brands will help expand the reach of these products, as reported by ICICI Securities. Pfizer has declared a dividend of ₹75 per share and ended FY26 with a cash balance of ₹31 billion. The brokerage maintains its bullish outlook on the stock based on these operational improvements and strategic initiatives.
